PARTICIPANT INFORMATION SHEET

TITLE:	STopping Aminosalicylate Therapy in Inactive Crohn's Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial
PROTOCOL NO.:	RP1610
SPONSOR:	Alimentiv
STUDY DOCTOR:	Dr Gordon Moran Nottingham Digestive Diseases Centre University Hospital Nottingham NG7 2UH
STUDY-RELATED PHONE NUMBER(S):	0115 823 1417
IRAS Number:	245233

You are being invited to take part in a research study.

Before you decide to participate, it is important for you to know why this research is being done and what it will involve. Please take your time to read the following information and to discuss it with others if you wish. Ask questions if anything is unclear or if you would like more information.

You are being asked to take part in this study because you have Crohn's Disease (CD) that is in remission and you are currently taking a type of medication known as an aminosalicylate (5-ASA or mesalazine) to treat your CD. Remission means that your CD is not currently flaring.

STATIC is a study supported by the British Society of Gastroenterology: the official body of the UK Gastroenterology Consultants.

What is the purpose of the study?

There are plenty of studies showing that 5-ASAs are very useful drugs in the treatment of Ulcerative colitis. Equally, there are plenty of studies showing that they are NOT useful in the treatment of Crohn's disease. In fact, they are little more than a placebo in Crohn's disease. To this effect, the British Society of Gastroenterology does not suggest using 5ASAs to treat CD. However, a large proportion of patients with Crohn's disease are still prescribed 5ASAs, even after other medication (like azathioprine or biologics) has been added to help control their symptoms.

This clinical trial will aim to definitively prove that 5ASAs have no role in the management of CD, and it is indeed safe to stop these medications when CD is in remission (i.e. currently not flaring). The study aims to show that stopping or continuing 5ASAs will not have any effect on disease flares and complications related to CD. The results from this study are therefore likely to change clinical practice, and inform doctors going forwards

If you decide to take part, what is involved?

Your doctor will have reviewed your medical and surgical history, as well as medications, to make sure you meet the study requirements. If you take part in the study, you will be asked to participate in four study consultations over a two-year period. These will take place either by telephone, video call, email or post.

Visit 1
At the first consultation which will be conducted either via telephone or video call, a research nurse, or other medical professional, will discuss the study with you and make sure that the study is suitable for you. You will also be able to ask questions about the study. If you are unsure whether to take part, you can ask to have another consultation or take longer to think about the study before making your decision.

If you are happy to join the study after this discussion, you will be asked to sign two copies of a consent form. The consent form confirms that you agree to take part and that you give us permission to look at your computerised medical records (now and for the duration of the study) from your GP and from any hospital you attend. Relevant sections of your medical records will be uploaded to the trial database to help with the trial's analysis.

After you have signed the consent form, we will ask some questions about your medical history and also ask you to complete a simple questionnaire. We will ask you to post one copy of the signed consent form and the questionnaire back to us in the pre-paid envelope provided.

We will also ask you if you are willing to collect a urine sample four times during your involvement in the study using the kit that will be provided (including return postage). This part of the study is optional.

Randomisation

Once we have received your paperwork, you will be allocated at random (by chance) to either:

GROUP 1: Continuation of your current 5-ASA treatment, in which you will be asked to continue taking the medication as prescribed by your doctor.
OR
GROUP 2: Discontinuation of your current 5-ASA treatment, in which you will be asked to stop taking the 5-ASA medication. If you are assigned to this group it is very important that you do not continue to take your current 5-ASA treatment.

After you have been assigned to one of these two study groups, you will continue in that group for the duration of your time in the study. We will send you details of which group you have been assigned to by post, and also email your GP to let them know.

Visits 2, 3 & 4 (Weeks 26, 52, 104)
At each of these visits, which will be performed by email or post, we will ask you to complete two questionnaires, and to collect a further urine sample, if you agreed to this during your consent consultation, using the kit that will be posted to you.

Between these visits, the study team may contact you by telephone or email to remind you about your participation and adherence to the treatment group to which you have been assigned.

What are the known risks of taking part in this study?

The risks in this study are those related to either continuing your usual 5-ASA treatment or ones related to stopping your 5-ASA treatment.

The risks of continuing your usual 5-ASA treatment are as previously discussed with your doctor prior to starting your 5-ASA therapy. If you have experienced side effects related to 5-ASA, these might go away if you discontinue your 5-ASA, but others may be long lasting or permanent.

Seeing that the vast majority of studies to date have shown that 5ASAs have a minimal role in CD, we do not feel that there is a significant risk in stopping them. Having said that, if you do experience any worsening of your health or CD symptoms, please contact your GP as soon as possible and inform the study team

What are the possible benefits to taking part in the study?

There may be no direct benefit to you from taking part in this trial, but the results may improve the understanding of the safety and effectiveness of 5-ASA in patients with CD who are in remission. This study has the potential to influence the treatment guidelines and care for all future patients with CD worldwide.

What are the alternatives to taking part in the study?

If you decide not to participate in this study you will continue to receive regular care from your doctor.

What are the costs of taking part in this study?

Participation in this research study is voluntary. All study procedures described above will be performed at no cost to you, and you will not be paid for taking part.

What if there is a problem?

If you have personal insurance, your participation in this study may affect your policy. Before agreeing to take part in this study, you should check that your medical insurance or other personal insurance (e.g. travel insurance) will not be affected.

Alimentiv (the Sponsor) has taken out appropriate insurance for the study. This insurance covers the sponsor for its accepted legal liabilities for harm caused to participants where that harm is a direct result of the study procedures and/or in case of direct result of protocol specific assessment. The NHS insurance/indemnity will cover liability of site staff for negligence.

Do you have to take part in this study and can you withdraw?

Participation in this study is voluntary. You may refuse to participate, refuse to answer questions or withdraw at any time with no effect on your future health care. You do not have to give any reason and your legal rights will not be affected.

If you decide to withdraw from the study, it is important to discuss your decision with your GP who can advise on what follow-up care/testing may be needed and arrange for your care to continue.

Your doctor, the study sponsor, or regulatory agencies may stop your participation in the study at any time without your consent if it appears to be in your best interest.
You may also be withdrawn from the study without your consent if:

- you fail to follow directions for participation in the study
- it is discovered that you are not eligible to participate in the study
- the study is stopped for any reason.

What if new information becomes available?

Any significant new findings learned during the course of the study, which might affect your willingness to continue participation, will be provided to you. If you decide to continue in the study, you will be given an

updated participant information sheet that explains the new findings and may be asked to sign an updated consent form.

What happens at the end of the study?

At the end of the study you will continue to receive standard care with your doctor. You may also discuss your treatment options to either continue with your aminosalicylate (5-ASA) treatment or stop taking it**.**

Will my taking part in the study be kept confidential?

All information collected about you during the course of the research will be kept strictly confidential, stored in a secure and locked office, and on a password protected database. Electronic data will be encrypted. Any information about you which leaves your GP practice will have your name and address removed (anonymised) and a unique study number will be used so that you cannot be recognised from it.

The only people who will have access to information that identifies you will be people who need to contact you for follow-up or those auditing the data collection process. The people who analyse the information will not be able to identify you and will not be able to find out your details. All these people have a duty to keep your information, as a research participant, strictly confidential.

While you are taking part in the study, we will request health related information about you from NHS Digital, the Department of Health body responsible for NHS Information Technology, or other relevant NHS bodies. Periodically, personal identifiable data, such as your unique NHS identifier (your "NHS number") and date of birth, will be sent securely to NHS Digital and we will obtain permission for them to provide further details about you. This may include, for example, details of any hospital stay or any other clinical event, such as a new diagnosis. Any information about you that leaves the hospital will have your name and address removed. A unique study number will be used so that you cannot be directly identified from it.

Data Protection Information / GDPR

Alimentiv (the sponsor) will be considered the data controller of your personal information in the context of the study. This means that they determine how and for what purposes your personal information are used and disclosed. They are responsible for looking after your information and using it properly in a fair, lawful and secure manner.
Your rights to access, change or move your information are limited, as we need to manage your information in specific ways to comply with legislation governing the conduct of research studies and to ensure the research output is reliable and accurate. If you withdraw from the study, we will keep the information about you that we have already obtained. To safeguard your rights, we will use the minimum personally identifiable information possible.

Data will always be transferred in a secure NHS-approved fashion. TCR Nottingham is the data processor of your data, responsible for the design, management, and security of the study database (http://www.tcrnottingham.com/Privacy/TCRPrivacyNotice.pdf). The study team will be responsible for managing access to your data.

If you agree to take part in the study, medical information, including medical history provided by other care givers, will be collected, and may be sent to the sponsor to be grouped together with other participant's information for analysis. Anonymised study documents may be collected after your direct participation in the research project ends.

Your information may also be inspected by auditors, to the extent permitted by applicable laws and regulations.

By signing the consent form you agree that your study information may be shared with others, (the sponsor), for the purposes of analysing study results, and/or to check that the study is being carried out correctly (Regulatory authorities, auditors and monitors). Your anonymised study data may also be used in the future by the sponsor, other companies and people working for or with the sponsor for research purposes unrelated to this current study.

Data collected during the study may be sent to associated researchers in countries where the laws do not protect your privacy to the same extent as the law in the UK, but the sponsor will take all reasonable steps to protect your privacy. With respect to transfers to its affiliates and business partners located outside of the European Economic Area (EEA), the Sponsor has put in place appropriate contractual provisions (e.g., so called "Standard Data Protection Clauses"), or is otherwise satisfied that there are measures in place to achieve the level of protection of coded personal information equivalent to that under European law.

During the life cycle of the study, the paper documents generated by the study will be maintained per ICH GCP Guidelines at Alimentiv in London, ON Canada. All documents are stored in a secure manner that restricts unauthorized access and in an environment that protects the integrity of the media in which the record is stored. Your study records will be kept at a secure location for a minimum of 25 years after study completion. You may ask to see your records and correct any errors: such a request must be made in writing and addressed to the trial centre.

It is important for you to be aware that if you are taking part in research, or information about you is used for research, your rights to access, change or move information about you are limited. This is because researchers need to manage your information in specific ways in order for the research to be reliable and accurate. If you decide to withdraw your consent for participating in the study, your records will be made available to the groups described above to check their accuracy, but no new information about you will be collected.

A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by UK Law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.

What will happen to any samples I give?

Urine samples taken from you will be held centrally at the trial centre in Nottingham, and then batch-shipped to the designated central laboratory at:
Dr Richard Kim's laboratory: University Hospital, London Health Science Centre, Rm C9-101, 339 Windermere Road, London, Ontario, N6A 5A5, Canada

Your samples will be labelled with your study assigned patient number. This number does not personally identify you. Samples once analysed will not be held but destroyed on site.

Who has reviewed the study?

The East of Scotland Research Ethics Service REC 2, which has responsibility for scrutinising all proposals for medical research on humans, has examined the proposal and has raised no objections from the point of view of research ethics. It is a requirement that your records in this research, together with any relevant

medical records, be made available for scrutiny by monitors from Alimentiv and University of Nottingham whose role is to check that research is properly conducted and the interests of those taking part are adequately protected.

What if there is a problem?

If you have a concern about any aspect of this study, please speak to the researchers who will do their best to answer your questions. Their contact details are given at the end of this information sheet.
You can also raise a complaint through the NHS Complaints Procedure. Details can be obtained from your GP or your local Patient Advice and Liaison Service (PALS) Office (https://www.nhs.uk/Service-Search/Patient-advice-and-liaison-services-(PALS), or telephone NHS 111 and request details of your local PALS Office).

You also have the right to file a complaint with your local data protection authority. You can do this by contacting the Information Commissioner's Office (ICO). Their telephone number is 0303 123 1113 and more information about reporting concerns can be found at https://ico.org.uk.

Signing the consent form
To confirm your willingness to participate in the study, you will be asked to sign the consent form. If you join the study, you do not waive any legal rights by signing the consent form, nor release your GP/ study doctor or sponsors from their legal and professional obligations.

What will happen to the results of the research study?

After the study has finished, we will publish the results in scientific journals and present them at scientific meetings. Your details will remain strictly confidential and you will not be directly identifiable by name from any such report or publication.

Who is organising and funding the research?

The sponsor of this study, Alimentiv, has obtained academic grants which are used to provide funding for this study.

Further details

If you would like to see a short video describing the study, please go to

https://static-trial.healthandcarevideos.com/.

How to contact us

If you have any questions or would like more information about the study please contact the Trial Centre: staticstudy@nottingham.ac.uk / 0115 823 1417.

Thank you for taking the time to read this information sheet

INFORMED CONSENT FORM

TITLE: STopping Aminosalicylate Therapy in Inactive Crohn's Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial

PROTOCOL NO.: RP1610

SPONSOR: Alimentiv

STUDY PI: Dr Gordon Moran

Patient Screening Number: ☐☐☐☐☐☐ --- ☐☐☐☐ By signing this consent form, I acknowledge that:	**Please initial each box:**
1. I have carefully read the information presented in this Participant Information sheet	
2. The purpose and procedures related to this clinical trial have been explained to me and I have had the opportunity to ask questions and all of my questions were answered to my satisfaction	
3. I have been informed of the parts of the study that are experimental and of the possible discomforts, risks and benefits	
4. I understand that I am free to withdraw this consent and discontinue my participation in this study at any time, and without my medical care or legal rights being affected	
5. I authorise the use and disclosure of my health records to the parties listed in the Confidentiality section of the Participant Information Sheet for the purposes described and for future research	
6. I agree to allow the study team to send me email reminders or contact me via telephone/video call regarding my participation and adherence to the treatment group that I have been assigned to, as well as for interviews about my health and the state of my Crohn's Disease	
7. I understand that periodically, personal identifiable data, such as my NHS Number and date of birth, will be sent securely to NHS Digital or other relevant NHS bodies, who will be able to provide details about any hospital admissions (Hospital Episode Statistics, HES) I experience, or details from the Office for National Statistics (ONS) in the event of my death. I understand that data will always be transferred in a secure fashion. I give permission for my data to be used in this way	
8. I understand that relevant sections of my medical notes, data collected in the study and applicable information from the ONS and HES will be uploaded to the study database and looked at by authorised individuals from the sponsor, the research team and regulatory authorities where it is relevant to my taking part in this study. I give permission for these individuals to have access to these records for the duration of the study and to collect, store, analyse and publish information obtained from my participation in this study. I understand that my personal details will be kept confidential except for the secure sharing of data with NHS Digital	

_____ _____ _____

Full Name of Participant (First name, Surname) **Date** **Signature**

If you agree to providing urine samples as part of the study, please complete the section below:

	Please initial box:
9. I understand and agree that urine samples provided by me will be shipped to the designated laboratory for analysis and disposal	